John G. Lemkey CPA serves as Chief Operating Officer of the Company. Mr. Lemkey has served as our Chief Operating Officer since November 2018. Mr. Lemkey previously served as our Chief Financial Officer from the Company’s inception in 2013 to November 2018. Since 2012, Mr. Lemkey has also served as Chief Operating Officer of Tang Capital Management, LLC, a life sciences-focused investment company and an affiliate of the Company, which Mr. Lemkey joined in 2006. From 2003 to 2006, Mr. Lemkey was a Senior Auditor at Ernst & Young LLP. Mr. Lemkey received a B.S. degree in accounting from the University of Southern California and is a Certified Public Accountant (inactive) in the state of California.
As the Chief Operating Officer of Odonate Therapeutics Inc, the total compensation of John Lemkey at Odonate Therapeutics Inc is $1,525,110. There are 1 executives at Odonate Therapeutics Inc getting paid more, with Joseph O'Connell having the highest compensation of $1,980,570.
John Lemkey is 39, he's been the Chief Operating Officer of Odonate Therapeutics Inc since 2018. There are 11 older and no younger executives at Odonate Therapeutics Inc. The oldest executive at Odonate Therapeutics Inc is Dr. Joseph P. O'Connell M.D., 66, who is the Chief Medical Officer.
John's mailing address filed with the SEC is 4747 Executive Dr, San Diego, CA 92121, USA.
Over the last 7 years, insiders at Odonate Therapeutics Inc have traded over $20,636,060 worth of Odonate Therapeutics Inc stock and bought 10,839,138 units worth $199,522,296 . The most active insiders traders include Capital, Llc Eco R1, Aaron I. Davis e Kevin Ctang Capital Partner.... On average, Odonate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $444,503. The most recent stock trade was executed by Capital, Llc Eco R1 on 1 December 2021, trading 5,887,610 units of ODT stock currently worth $9,714,557.
Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
Odonate Therapeutics Inc executives and other stock owners filed with the SEC include: